Segment Information (Tables)

3 Months Ended

Mar. 31, 2012

Segment Information [Abstract]

Schedule Of Financial Data For Two Business Segments

	Three months ended
	March 31,			March 31,
	2012			2011
Revenues:
Par Pharmaceutical	$	251,167		$	209,745
Strativa		20,305			23,207
Total revenues	$	271,472		$	232,952
Gross margin:
Par Pharmaceutical	$	82,450		$	92,559
Strativa		15,396			17,093
Total gross margin	$	97,846		$	109,652
Operating income (loss):
Par Pharmaceutical	$	24,048		$	(132,746	)
Strativa		(45,261	)		(5,817	)
Total operating loss	$	(21,213	)	$	(138,563	)
Interest income		136			423
Interest expense		(3,094	)		(150	)
Provision (benefit) for income taxes		4,525			(29,446	)
Loss from continuing operations	$	(28,696	)	$	(108,844	)

Schedule Of Total Revenues Of Top Selling Products

Product	Three months ended
	March 31,			March 31,
	2012			2011
Par Pharmaceutical
Metoprolol succinate ER (Toprol-XL®)	$	61,765		$	63,418
Budesonide (Entocort® EC)		37,984			-
Propafenone (Rythmol SR®)		19,092			22,039
Sumatriptan succinate injection (Imitrex®)		16,700			16,699
Chlorpheniramine/Hydrocodone (Tussionex®)		13,957			12,679
Bupropion ER (Wellbutrin®)		11,354			-
Dronabinol (Marinol®)		7,603			6,871
Zolpidem (Ambien CR®)		6,921			-
Tramadol ER (Ultracet ER®)		5,829			6,081
Cholestyramine Powder (Questran®)		4,652			3,683
Meclizine Hydrochloride (Antivert®)		4,186			4,875
Nateglinide (Starlix®)		4,024			4,306
Amlodipine and Benazepril HCl (Lotrel®)		2,448			18,171
Clonidine TDS (Catapres TTS®)		(991	)		5,806
Other (1)		50,250			37,228
Other product related revenues (2)		5,393			7,889
Total Par Pharmaceutical Revenues	$	251,167		$	209,745
Strativa
Megace® ES	$	12,178		$	14,085
Nascobal® Nasal Spray		5,931			3,878
Oravig®		155			749
Zuplenz®		85			221
Other product related revenues (2)		1,956			4,274
Total Strativa Revenues	$	20,305		$	23,207

(1) No single product in the other category is in excess of 3% of total generic revenues for the three-month period ended March 31, 2012 or for the three-month period ended March 31, 2011.

(2) Other product related revenues represents licensing and royalty related revenues from profit sharing agreements related to products such as diazepam rectal gel, the generic version of Diastat^®, and fenofibrate, the generic version of Tricor^®. Other product related revenues included in the Strativa segment relate primarily to Strativa's share of the proceeds from Optimer Pharmaceuticals' sale of certain rights in fidaxomicin to a third party.